OOIR: Observatory of International Research

Papers

(The H4-Index of Nature Reviews Rheumatology is 58. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Low-dose rituximab can go even lower	731
No benefit from adding MTX to ustekinumab	469
Inflammatory arthritis affects men’s fertility	397
Bimekizumab effective across the axSpA spectrum	393
SLC26A2 deficiency, matrix stiffness and mechanotransduction linked in osteoporosis	274
Genome-wide mutagenesis reported in systemic sclerosis	244
The role of the patient in rheumatology	219
Osteoarthritis as a systemic disease	190
Reply to ‘Potential benefit of anticoagulation in Behçet syndrome’	180
A role for TGFβ and EBV in MIS-C pathogenesis	162
COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations	158
Rheumatic diseases on the rise	150
Biological and clinical roles of IL-18 in inflammatory diseases	149
Towards better management of sterile bone inflammation	140
New drug formulation reduces bone loss	138
Use of platelet-rich plasma for knee OA not supported by RCT results	137
To choose or not? The value of discrete-choice experiments in rheumatology	134
Urchin-like nanoparticles for miRNA therapy of OA	129
The value of comparative efficacy studies in informing rheumatology guidelines	125
The 2022 ACR vaccination guideline: a call-to-action	123
2021 ACR guideline for JIA reflects changes in practice	121
Addressing the challenge of global delays in diagnosis and treatment of systemic lupus erythematosus	119
Down syndrome: insights into autoimmune mechanisms	113
Appraising the evolving landscape of protease inhibition in osteoarthritis	112
Inflammation across tissues: can shared cell biology help design smarter trials?	112

Imbalance of threat and soothing systems in fibromyalgia: rephrasing an established mechanistic model?	107
FOXP3 splice variant is associated with autoimmune disease	105
MIS-C: myths have been debunked, but mysteries remain	103
Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician	102
Low-dose glucocorticoids benefit seniors with RA	101
Co-trimoxazole reduces mortality in anti-MDA5-DM	100
Pain in systemic lupus erythematosus: emerging insights and paradigms	98
Guiding ILD management in systemic autoimmune rheumatic diseases	98
Low back pain is a growing concern	98
Wnt-induced IGF1 drives OA	94
Author Correction: Proposals for the rheumatological use of JAK inhibitors	92
Biologics in rheumatoid arthritis: a lifetime treatment or possibility of drug holidays?	92
A direct link between SARS-CoV-2 and bone loss	89
S100A4 inhibition targets fibrosis in SSc	87
Fumarate drives interferon release in systemic sclerosis monocytes	86
Calprotectin tracks tocilizumab-treated RA	82
Distinct mucosal endotypes as initiators and drivers of rheumatoid arthritis	82
Sexual dimorphism in the prevalence, manifestation and outcomes of axial spondyloarthritis	79
Rheumatic diseases and metabolism: where centre and periphery meet	77
Publisher Correction: Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician	77
Rheumatology in the digital health era: status quo and quo vadis?	74
Erosive cargo from synovial fibroblasts	74
Targeting the IVD clock to halt degeneration	72
Which DMARD for ICI-associated arthritis?	71
sCD13 role in arthritis mediated via bradykinin receptor	71
Publisher Correction: Recent advances in the diagnosis and management of neuropsychiatric lupus	70
Macrophage-coated nanocarriers for gouty arthritis	69
PGE2 receptor antagonist has potential to treat osteoarthritis	69
A path towards personalized medicine for autoinflammatory and related diseases	67
Insights into IVDD pathogenesis in 2024	67
Cell-free DNA fragmentation signatures link cancer and autoimmunity	66
ERAP1 and the return of the UPR in ankylosing spondylitis	63
Chimeric receptors broaden the therapeutic landscape for autoimmune disease	59
Phase III trial of telitacicept in SLE	58